Eisbach Bio

Eisbach Bio is a clinical-stage, privately held biotechnology company based in Munich, Germany, focused on the discovery and development of next-generation small-molecule cancer therapies. Rather than pursuing conventional inhibitor approaches, the company targets the activated state of enzymes — the molecular machinery that tumors depend on — in order to exploit genetically defined cancer vulnerabilities. Its work is grounded in the concept of synthetic lethality: disabling the regulated biological activity that cancer cells uniquely rely on, thereby triggering cancer cell death while sparing healthy tissue. The company's proprietary ALLOS platform combines wet-lab and computational screening on full-length enzyme complexes in their physiologically activated state, including natural allosteric activators, with AI-guided molecular design. Eisbach argues that most small-molecule inhibitors are discovered using simplified assays that strip targets of their natural regulation, creating a gap between laboratory promise and patient benefit. By starting from biological regulation as it exists in vivo, the company aims to identify unique molecular vulnerabilities and design drugs that selectively suppress them. Eisbach Bio describes itself as a clinical-stage company, indicating that at least one of its programs has advanced into human testing, and it invites visitors to explore its pipeline and clinical trial information. Its programs are advanced through an evidence-driven approach integrating mechanistic insight, structural biology, artificial intelligence, and translational development. The company is privately held and operates from the Munich area, with a Wikidata entry placing it in Planegg, a municipality adjacent to Munich. Its multidisciplinary, international team spans oncology, mechanistic biology, chemistry, AI-supported iterative drug design, and clinical development. Publicly available team profiles include researchers and clinical operations staff such as Alessandro S. Bordonaro (preclinical), Narcisa Marinescu (clinical operations), Uthira Muralitharan (preclinical), and William Menzer (medicinal chemistry). The company positions itself within the next era of oncology, aiming to deliver transformative and sustainable cancer medicines by addressing the core mechanisms of tumor growth and resistance.

Eisbach Bio is a clinical-stage, privately held biotechnology company based in the Munich area of Germany. Its Wikidata entry identifies it as a company in Planegg, a municipality in Bavaria immediately southwest of Munich, while the company's own materials describe it as based in Munich. The company was founded to pursue a differentiated approach to oncology drug discovery, centered on targeting the activated state of enzymes rather than the conventional inhibition strategies that dominate small-molecule cancer therapy. The scientific premise behind Eisbach Bio is that many cancer therapies are limited by a "toxicity barrier": drugs that attack cancer cells can also harm healthy tissue, producing severe side effects, while tumors evolve resistance that limits the durability of patient responses. The company frames this as a limitation of conventional inhibitor drugs rather than of the underlying cancer biology. Its response is to harness synthetic lethality — targeting genetic vulnerabilities unique to cancer cells — by disabling the activated state of the molecular machinery tumors depend on, thereby triggering cancer cell death while sparing healthy tissue. To execute this strategy, Eisbach Bio built the proprietary ALLOS platform. The platform is built on two principles. First, "real biology first": most cancer drugs are small-molecule inhibitors discovered using simplified assays that remove targets from their natural regulation, creating a gap between laboratory promise and patient outcomes. Eisbach therefore begins drug discovery with biological regulation as it exists in vivo. Second, "screening beyond the tube": the company conducts wet-lab and computational screens on full-length enzyme complexes in their physiologically activated state, including natural allosteric activators, so that targets are observed within complex biological systems rather than in isolation. This allows the company to identify unique molecular vulnerabilities. The company integrates deep mechanistic insight, structural biology, artificial intelligence, and translational development into a disciplined, evidence-driven program. Its multidisciplinary, international team combines expertise in oncology, mechanistic biology, chemistry, AI-supported iterative drug design, and clinical development. Publicly listed team members include Alessandro S. Bordonaro and Uthira Muralitharan in preclinical roles, Narcisa Marinescu in clinical operations, and William Menzer in medicinal chemistry. As a clinical-stage company, Eisbach Bio has advanced at least one program into clinical testing and directs visitors to its pipeline and clinical trial information. It remains privately held and describes its mission as translating the complexity of genome regulation in cancer into precise, safe, and transformative therapies for patients, with a long-term vision of delivering transformative and sustainable oncology medicines.

Clinical-stage oncology biotechnology company targeting the activated state of enzymes via synthetic lethality and AI-guided drug discovery.

• ALLOS platform

  Proprietary AI-guided drug discovery platform that screens full-length enzyme complexes in their physiologically activated state, including natural allosteric activators, to identify cancer-specific vulnerabilities.

• Clinical-stage oncology pipeline

  Next-generation small-molecule cancer therapies targeting the activated state of enzymes, advanced through mechanistic insight, structural biology, AI, and translational development.

1. 1Home | Eisbach Bioeisbach.bio
2. 2About Us | Eisbach Bioeisbach.bio
3. 3Eisbach Bio (Germany) - Wikidatawikidata.org